Our Annual Cancer Immunotherapy Update – Life Science Leader Magazine
|
Our Annual Cancer Immunotherapy Update
Life Science Leader Magazine When we started our series, “Combination Cancer Immunotherapy — A Virtual Roundtable,” in 2014, our basic assumptions were not the consensus view. We assumed immunotherapy, now more commonly called immuno-oncology (IO), would become the … |
Genetic Literacy Project |
‘A Crack in Creation’: Jennifer Doudna’s CRISPR memoir is flawed, but convincing
Genetic Literacy Project The prospect of a memoir from Jennifer Doudna, a key player in the CRISPR story, quickens the pulse. And A Crack in Creation does indeed deliver a welcome perspective on the revolutionary genome-editing technique that puts the power of evolution into … |
Phys.Org |
‘Immunoswitch’ particles may be key to more-effective cancer immunotherapy
Phys.Org For their study, the Johns Hopkins researchers combined two different immunotherapy strategies on manmade nanoparticles about 1,000 times smaller in diameter than a human hair, similar to drug-delivery platforms already in use in some cancer therapies, … |
Thorold News |
BRIEF-Sangamo Therapeutics updates on SB-525 investigational hemophilia A gene therapy
Reuters Reuters is the news and media division of Thomson Reuters. Thomson Reuters is the world’s largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news … Sangamo: SB-525 Therapy Receives Orphan Medicinal Product Designation From EMAMarkets Insider |
Cancer Network |
Immunotherapy Yields ‘Dramatic’ Response Rates in Relapsed Mesothelioma
Cancer Network CHICAGO—Immunotherapy may represent an effective new treatment approach for relapsed mesothelioma patients, according to a new study. Anti–programmed death-1 (PD-1) immunotherapy may have activity as second- or third-line therapy in malignant … |
Agriculture et Environnement |
La merveilleuse aventure des pionniers de CRISPR/Cas9
Agriculture et Environnement Après les méganucléases, les doigts de zinc et les TALEN, la dernière génération CRISPR-Cas9 et CRISPR–Cpf1 représente une véritable rupture technologique, comme on en connaît peu par décennie, par siècle », indique le rapport. Fruits de la recherche … |